Necitumumab + Gemcitabine + Carboplatin
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Squamous Non-Small Cell Lung Cancer
Conditions
Locally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer
Trial Timeline
Nov 1, 2016 → Feb 1, 2019
NCT ID
NCT02941601About Necitumumab + Gemcitabine + Carboplatin
Necitumumab + Gemcitabine + Carboplatin is a phase 2 stage product being developed by Eli Lilly for Locally Advanced Squamous Non-Small Cell Lung Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02941601. Target conditions include Locally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02941601 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Locally Advanced Squamous Non-Small Cell Lung Cancer